Additives screening for the formulation of solid lipid nanoparticles of alpha-mangostin

This is the authors' abstract. We don't add key points for this paper.

The purpose of the study is to perform pre-formulation studies for alpha-mangostin (α-mangostin)and screening of additives (such as solid lipids, emulsifiers and cryoprotectants) and their combinations (ratio oflipids, ratio of drug: lipid, ratio of emulsifier: co-emulsifier and concentration of cryoprotectant) used in theformulation of solid lipid nanoparticles of α-mangostin. This screening is essential for the formulation of solid lipidnanoparticles (SLNP) that provide small particle size and PDI, high entrapment efficiency and zeta potential. Thisscreening offers a rationale for selecting additives and their concentrations for formulating optimized SLNP. Pre-formulation studies showed melting point of 181.5°C, partition coefficient of 0.359 and drug solubility of 0.3072,0.4576, 0.4892 and 0.5782 mg/mL in 1.2, 6.8, 7.0 and 7.5 pH buffers respectively. Ultimately, the DSC thermogramdefines the sharp endotherm of α-mangostin at 195.98°C. Hot melt homogenization followed by ultrasonicationtechnique is used to develop solid lipid nanoparticles. Process parameters such as homogenization speed (15,000rpm) and ultra sonication (6 minutes) was optimized based on particle size and PDI. The optimized formulation ofSLNP of α-mangostin contain 1:2:0.5:0.5:5 ratio of Drug: Solid lipid (0.8:1.2 ratio of Stearic acid: Precriol ATO5):Poloxamer 407: Sodium taurocholate: Mannitol.